Swiss study slams Merck and FDA on Vioxx
Article Abstract:
A study funded by the Swiss National Science Foundation by analyzing 18 randomized controlled Vioxx trials and 11 observational studies show that 41 patients out of 11,000 Vioxx users had suffered heart attacks by late 2000. Lancet editor, Richard Horton, faulted Merck Co. for 'astonishing failure' in monitoring the post-marketing safety for its drug and criticized FDA for 'lethal weakness' in regulatory oversight.
Publication Name: Philadelphia Inquirer (PA)
Subject: Business, regional
ISSN: 0885-6613
Year: 2004
User Contributions:
Comment about this article or add new information about this topic:
Merck among leaders in AIDS vaccine research
Article Abstract:
Merck and company Inc. is the most promising and broad-based AIDS vaccine research in Philadelphia. Merck's lead AIDS vaccine candidate uses a weakened common-cold virus, known as adenovirus, which when injected into muscle cells, carries genetic material from the AIDS virus into the body which produce an immune response to the virus.
Publication Name: Philadelphia Inquirer (PA)
Subject: Business, regional
ISSN: 0885-6613
Year: 2003
User Contributions:
Comment about this article or add new information about this topic:
Just Merck's latest setback: Patent expirations, research mishaps, and few products to replace aging top sellers hinder the world's fourth-largest
Article Abstract:
Merck and Company Inc.'s decision to stop selling its arthritis pain drug Vioxx is the latest setback for the giant drugmaker. Merck shares and the stock price came down 27 percent as investor reacted immediately after the companies decision to stop the production of Vioxx due to patent expirations and research problems.
Publication Name: Philadelphia Inquirer (PA)
Subject: Business, regional
ISSN: 0885-6613
Year: 2004
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Internet to get an upgrade. Pegasus, a local research project, will receive funding to help speed up the Next Generation Internet
- Abstracts: Lucent the latest firm in crisis to call back a former CEO. N.J. firm's stock soars after offer from Fuji. New steel firm bids to add to its assets
- Abstracts: She finds the story among the statistics: Economist needs the smarts to turn numbers to words. Support, networks for jobless
- Abstracts: Claiborne offers a new outfit in Mexx. Gambling lobbyists keep eyes on Philadelphia: New Jersey casinos are hedging their bets in Harrisburg
- Abstracts: Vehicles' lineage not clear-cut now. Keeping meat safe for the table